华润双鹤药业股份有限公司关于公司药品新进国家医保目录的公告

Core Viewpoint - The inclusion of the product Methylphenidate Hydrochloride Extended-Release Capsules in the National Medical Insurance Directory is expected to positively impact the company's market promotion and sales performance [3]. Group 1: Product Inclusion in Medical Insurance - The product Methylphenidate Hydrochloride Extended-Release Capsules has been included in the National Medical Insurance Directory for 2025, with the agreement period allowing for Class B payment [1]. - The application price for the product remains confidential, and the payment standard is marked as * [1]. Group 2: Sales Performance - The product received approval from the National Medical Products Administration on January 8, 2025, and generated sales revenue of RMB 12.4 million in the first three quarters of 2025 [2]. - Following the acquisition of a 53.28% stake in Henan Zhongshuai Pharmaceutical Technology Co., Ltd. in August 2025, the sales revenue from this product accounted for approximately 0.15% of the company's total revenue for the same period [2]. Group 3: Impact on Company Performance - The inclusion of the product in the National Medical Insurance Directory is anticipated to enhance market promotion and sales, positively affecting the company's operational performance [3]. - The implementation of the National Medical Insurance Directory is set for January 1, 2026, and is not expected to have a significant impact on the current year's operational performance [3].